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Summary
Objective: To determine the prevalence of human papillomavirus (HPV) genotypes 6, 11, 16, 18,
and 31 in Mexican women living in rural areas of Puebla, Mexico and to evaluate risk factors
associated with cervical neoplasm in this population.
Methods: A cross-sectional studywas conducted in 326women at the General Hospital of Metepec,
Puebla. Cervical samples were obtained using a cytobrush and tested for HPV genotypes by PCR
assays using type-specific primers. A questionnaire was completed regarding gynecological,
obstetric, and sexual behavior of the patients.
Results: The overall prevalence of HPV infection was 25.4%, with two peaks of higher HPV
prevalence in those aged 18—24 and 55—64 years. The individual genotype prevalences were:
9.6% HPV6, 4.8% HPV11, 54.2% HPV16, 37.3% HPV18, and 9.6% HPV31. Number of pregnancies was
the most important risk factor associated with cervical cancer.
Conclusions: HPV16was themost common type found in all cervical lesions. Genotype 16 or 18was
detected in patients with a diagnosis of cervical cancer. We found two peaks of age-specific HPV
prevalence similar to findings reported worldwide.
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Cervical cancer (CC) is a major public health problem in
Mexico.1 Human papillomavirus (HPV) is the main causal
factor of CC, but there are other risk factors that contribute
to the development of CC such as smoking, multiple preg-Published by Elsevier Ltd. All rights reserved.
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and family history of CC.2
The global prevalence of HPV infection in women with a
normal cytology is estimated to be 10.5% worldwide;3 how-
ever, HPV prevalence has been found to vary by nearly 20
times among different populations, from 1.4% in Spain to
25.6% in Nigeria.4
Because the presence of HPV in Papanicolaou (Pap) smears
has been associated with a very high relative risk of existing
cervical intraepithelial neoplasm or CC, detection of HPV
DNA has been proposed as a necessary complement to cyto-
logical testing in cervical screening.5,6
More than 100 HPV genotypes have been described. Of
these, more than 40 HPV types infect the human anogenital
tract.7 HPV types are classified into low or high risk on the
basis of their association with premalignant and malignant
lesions.8 Considering that different types of HPV vary in tissue
affinity and pathogenicity, the determination of HPV geno-
type is commonly used as the exposure measure associated
with the risk for developing invasive CC.9 In this regard, HPV
type 16 is involved in approximately 54% of all cases of
invasive CC worldwide, whereas HPV type 18 causes about
11%.10 Other HPV genotypes are less frequently associated
with cancer.
HPV types most commonly detected in women with nor-
mal cytology are similar to those found in pre-neoplastic and
cancer cells, although the detection frequency of HPV types
16 and 18 is substantially lower in women with normal
cytology than in neoplastic tissues.3
HPV types 16, 18, 31, 45, 53, and 58 have frequently been
found in cervical samples from Mexican women.11—13 Yet
little is known regarding HPV prevalence in women with
and without CC in different Mexican populations. Most stu-
dies have been performed in Mexico City, and the prevalence
obtained has varied depending on the study. In cancer sam-
ples, HPV has been detected in from 87% to 95.5%, in high-
grade squamous intraepithelial lesions (HGSIL) from 83% to
91.6%, in low-grade squamous intraepithelial lesions (LGSIL)
from 33% to 66.7%, and in normal smears from 17% to
23.1%.14,15
The general prevalence of HPV in women from
Durango City (located in northern Mexico) has been esti-
mated at 4.8%,12 but a higher prevalence has been
reported for HPV in Mexico City (20.4%).3 Little is known
about the molecular epidemiology of HPV in the state of
Puebla.
Therefore, we performed a descriptive and cross-sec-
tional study in order to determine the prevalence of HPV
infection and HPV genotypes in cervical scrapes from women
living in a rural region of Puebla, Mexico and to identify other
risk factors associated with HPV infection and cervical neo-
plasm in this population.
Methods
Study population
We studied 326 women requesting a cervical Papanicolaou
examination at the General Zone Hospital No. 5 of the
Mexican Institute for Social Security (IMSS) located in Mete-
pec, Puebla, Mexico. This second-level hospital is situated50 km from the city of Puebla and treats patients from the
rural communities of Atlixco and Izu´car in the state of
Puebla. All participants were enrolled consecutively from
May 2006 to August 2007.
The study was approved by the institutional ethics com-
mittee. The purpose and procedures of the study were
explained to patients, and informed consent was obtained
from all participants.
Patient characteristics such as age, place of residence,
age at first sexual intercourse, number of sexual partners,
number of pregnancies, and smoking habits were also
analyzed.
Collection of specimens
Two cervical samples were obtained from each patient
using a cytobrush. The first sample was used for cytological
diagnosis. Pap smears were evaluated by a pathologist
according to the Bethesda diagnosis criteria.16 The second
sample was used to detect HPV by PCR. In addition to the
Pap smear, each woman underwent colposcopy and, when
necessary, a biopsy.
DNA extraction
Cervical smears were placed in tubes containing 5 ml phos-
phate-buffered saline (PBS), shaken vigorously, and centri-
fuged for 10 min at 4000  g. The pellets were resuspended
in 1 ml PBS, and an aliquot of 0.5 ml was used for DNA
extraction using the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany). Purified DNAwas suspended in 100 ml of water. All
samples were tested for integrity of DNA by 1% agarose gel
electrophoresis.
PCR assays
Detection of HPV genotypes 6, 11, 16, 18, and 31 was
carried out using primer-specific PCR.17 Amplification
reactions containing a final volume of 25 ml were per-
formed with Taq PCR Master Mix Kit (Promega, Madison,
WI, USA), 0.2 mM concentrations of each primer, and
10.5 ml of DNA sample. Forty amplification cycles were
performed with a thermocycler (PTC 200, MJ Research,
Watertown, MA, USA). Each cycle consisted of a denaturing
step at 95 8C for 1 min followed by a primer annealing step
for 1 min at 55 8C for HPV types 16 and 31 or at 60 8C for
HPV types 6, 11, and 18, and a chain elongation step at
72 8C for 1 min. Finally, 15 ml of the amplification product
was analyzed by 1.5% agarose gel electrophoresis. A frag-
ment of the cyclophilin gene was amplified as internal
control.18 Gels were stained with ethidium bromide
(1 mg/ml), observed with a UV transilluminator, and photo-
graphed using a digital camera (DC290, Kodak, Rochester,
NY, USA).
Statistical analysis
Frequencies of clinical data were calculated, and differences
between groups were estimated by Chi-square test; p < 0.05
was considered significant. Results were analyzed using SPSS
for Windows, v.12 (Chicago, IL, USA).
Table 1 Prevalence of HPV genotypes in Puebla, Mexico
Cytological diagnosis No. of samples HPV16 HPV18 HPV31 HPV6 HPV11
Normala 34 2 (5.9) 2 (5.9) 0 1 (2.9) 0
LGSIL 233 30 (12.9) 23 (9.9) 4 (1.7) 5 (2.1) 3 (1.3)
HGSIL 51 7 (13.7) 5 (9.8) 4 (7.8) 2 (3.9) 1 (2.0)
CC 8 6 (75) 1 (12.5) 0 0 0
Total 326 45 (54.2)b 31 (37.3)b 8 (9.6)b 8 (9.6)b 4 (4.8)b
Results are n (%). HPV, human papillomavirus; LGSIL, low-grade squamous intraepithelial lesion; HGSIL, high-grade squamous intraepithelial
lesion; CC, cervical carcinoma.
a Samples were classified as normal if they did not present alterations either at cytology or colposcopy.
b Results included co-infections.
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Prevalence of HPV types
A total of 326 Mexican women living in a rural region of the
state of Puebla, Mexico were analyzed. Based on their cyto-
logical characteristics, samples were diagnosed as follows:
34 normal, 233 LGSIL, 51 HGSIL, and eight samples presented
CC (Table 1). The overall prevalence of HPV in the studied
population was 25.4%. As expected, the highest HPV preva-
lence was found in women with CC (87.5%), followed by
women with HGSIL (29.4%), LGSIL (24.0%), and normal cytol-
ogy (14.7%).
With respect to viral genotyping, 6/8 samples with CC
presented HPV type 16, one presented HPV type 18, and the
other was negative for all analyzed HPV genotypes.
HPV16 was the most frequently detected genotype with
an overall prevalence of 54.2% (including co-infections).
Prevalence of HPV type 16 increased in relation to neoplastic
alteration: 5.9% in normal samples, 12.9% in LGSIL, 13.7% in
HGSIL, and 75% in CC samples (Table 1). It is noteworthy that
11/45 HPV type 16-positive patients presented co-infection
with one or more of the other genotypes (Table 2). In this
regard, multiple HPV types were detected in 3.4% of the
studied patients. Of the HPV-positive samples, 11.8% pre-
sented co-infections and, of the HPV type 16-positive sam-
ples, 24.4% had other HPV types. Multiple co-infections
always included genotype 16 and never involved mixtures
of low-risk HPV genotypes.
The overall prevalences of HPV types 18, 31, 6, and 11
were 37.3%, 9.6%, 9.6%, and 4.8%, respectively. It is impor-
tant to note that we obtained three samples from the HGSIL
group infected with only low-risk HPVs, and these corre-Table 2 HPV type 16 and other types in co-infected cervical sam
Diagnosis Number of samples presenting mixtures of HPV
na 16 16/18 16/31
Normal 2 2 0 0
LGSIL 30 22 2 1
HGSIL 7 4 1 1
CC 6 6 0 0
Total 45 34 3 2
HPV, human papillomavirus; LGSIL, low-grade squamous intraepitheli
cervical carcinoma.
a Total of HPV type 16-positive samples.sponded to women with a high number of pregnancies (nine
and 15).
Multiple infections with different viral genotypes were
detected in the group of LGSIL and HGSIL, but not in the CC
and normal samples (Table 2).
Age-specific HPV prevalence
Patients were stratified into groups according to age and
presence of HPV infection. The overall prevalence of HPV
infection was high among young women (1824 years),
decreased slightly in the 25—34- and 35—44-years age groups,
dropped drastically at 4554 years, and increased to reach
the highest level at 5564 years (Figure 1). When we ana-
lyzed the presence of HPV type 16 and type 18 infections
separately we observed that HPV18 presented the highest
prevalence in young women (18—34 years) and decreased
with age, whereas HPV16 had two peaks of highest preva-
lence in those aged 35—44 and 55—64 years.
The mean age of women with multiple infections was 41.8
years, but no association with any age group was found.
Association between cervical lesions and clinical
variables
The mean age of women enrolled in this study was 41.5 years
(range 18—85 years). The mean age of those in the CC group
was 52.7 years, in the HGSIL group was 50.3 years, in the
LGSIL group was 38.7 years, and in the normal cytological
group was 45.2 years.
The mean age at first intercourse for all the women
enrolled in the study was 18.8 years (range 1436 years).ples
genotypes
16/6 16/11 16/31/6 16/18/31
0 0 0 0
3 1 0 1
0 0 1 0
0 0 0 0
3 1 1 1
al lesion; HGSIL, high-grade squamous intraepithelial lesion; CC,
Figure 1 Age-specific human papillomavirus (HPV) prevalence.
Table 3 Reproductive variables
Variable Group Mean  SD
Age Normal 45.23  14.97
LGSIL 38.70  10.73
HGSIL 50.35  15.79
CC 52.75  14.53
Age at first sexual intercourse Normal 19.06  2.46
LGSIL 18.67  4.07
HGSIL 19.53  3.3
CC 18.50  3.5
Number of pregnancies Normal 3.87  2.32
LGSIL 3.62  2.41
HGSIL 5.44  3.93
CC 6.87  4.18
LGSIL, low-grade squamous intraepithelial lesion; HGSIL, high-
grade squamous intraepithelial lesion; CC, cervical carcinoma.
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was very similar to that of the normal group (19.1 years).
Smoking was not found to be an important risk factor in
this population, because most of the women were non-smo-
kers (93.8%).
Women in the study had had a mean of four pregnancies,
and an association between positive history of multiple
pregnancies (>5) and neoplasia grade was found
( p < 0.05); thus, this was an important risk factor in the
studied population (Table 3).
Discussion
CC is the most frequent cancer in Mexican women,1 and HPV
is the main causal agent associated with its development.19
Different studies have shown that the prevalence of HPV
depends on several factors including economic development
of the society, education, and sexual behavior, among others.
Thus, it is higher in less-developed countries (15.5%) than in
countries that are more developed (10.0%).3 In this study we
found a 25.4% overall prevalence of HPV types 6, 11, 16, 18,
and 31 infection in women seeking treatment at the General
Hospital of Metepec Puebla. This group does not represent an
open population; therefore, prevalence may vary if healthy
subjects were considered.
An HPV prevalence of 20.4% has been reported for Mexico.
Other countries have reported higher prevalences of HPVinfection, e.g., Kenya, Mozambique, Zimbabwe (31.6%), and
Russia (29.1%).3,20 In our study we detected the presence of
HPV types 16 and 18 in 7/8 CC samples; however, this does not
discard the presence of non-tested HPV genotypes in the
other samples with CC. Other studies conducted in Mexican
women have reported HPV prevalence of 92% in CC samples.
Genotypes 16, 18, 31, 58, and 52 are the most common of
all the HPVs that infect women worldwide, representing 50%
of all HPV infections. However, HPV16 is the most prevalent
worldwide, with the exception of eastern Africa, Japan, and
Taiwan where the most common type is HPV52.3 The overall
prevalence of HPV16 found in this study (54.2%) is consistent
with that of other studies reporting prevalence of 34.7% to
59.6% for this virus type.2 The prevalence of HPV16 in
invasive CC cases was 75% in our study, similar to the pre-
valence (72.2%) found in similar samples in other studies
involving Mexican women.13 The differencemay be the result
of the low number of CC samples tested in our study.
HPV18 is one of the most common HPV types worldwide,
and in our study it was the second most prevalent genotype
(37.3%). A previous study in Mexican women reported HPV58
as the second most common viral type in LGSIL and HGSIL,
whereas HPV18 occupied the second place in CC.13 Our
results do not exclude the presence of HPV58 in the analyzed
samples because we did not determine this virus type. There-
fore, it is probable that our data misrepresent the actual
prevalence of HPV genotypes in the studied population.
A significant risk (18 times greater) for developing cancer
has previously been found in Caucasian and Latin American
women living in Los Angeles, CA, USA and who initiated their
sexual activity before 16 years of age.21 Similar data were
found in another study in Mexican women.22 In our study,
however, we did not find a relation between age at first
sexual intercourse and grade of neoplasia.
Concurrent infection with more than one genotype has
been observed in 11.4% of women infected with HPV.23 In our
study we found 11.8% of multiple infections. This value may
be higher because of the lack of diagnosis of certain viral
types that could increase the prevalence of multiple infec-
tions. Co-infections with multiple types have been observed
more frequently in younger women.24 We also found a mean
age of 41.8 years in patients with multiple infections, but the
presence of co-infections wasmore frequent in older women.
Other studies have shown the presence of co-infections
caused by several HPV genotypes including or excluding
HPV type 16. In our investigation, all co-infections involved
HPV type 16 and one or more of the other virus types.
Age-specific HPV prevalence has been estimated in dif-
ferent studies worldwide. After the age of 25 years, HPV
prevalence is higher in less-developed countries than in
developed countries, but both show a continuous decline
with increasing age until 4554 years when estimates
increase in both regions.3,25 We found a peak in the 18—
24- and 25—34-years age groups and a decrease in prevalence
until 55—64 years, where we found a second peak of pre-
valence. This second peak has been reported in other studies
and may be attributed to a cohort effect or to a reactivation
of latent viruses.25 Certain studies have shown a decrease in
HPV prevalence in the 35—44 years age group, but it has been
reported that in less-developed countries, after the age of 25
years HPV prevalence is higher than in developed countries.
The second peak of prevalence has been observed world-
694 N. Vela´zquez-Ma´rquez et al.wide, with the exception of Asia, where rates continue to
decrease.3
The mean age of the group with CC was 52.7 years, in
agreement with that reported in other studies with a mean of
50 years. The mean age for the group with HGSIL was 50.3
years, whereas other studies report 28 years. These results
suggest that in our population there is no incubation period
for the progression of HGSIL to CC, similar to other popula-
tions. This may be a factor that explains in part the high rates
of CC in Mexico, but this requires further investigation.26—30
The most important risk factor associated with cervical
neoplasia grade was number of pregnancies. The CC group
presented a mean of 6.9 pregnancies in contrast with the
LGSIL group of women who presented a mean of 3.6 parities.
A relationship between neoplasia grade and positive history
of more than five pregnancies was found. Number of preg-
nancies is a risk factor reported in epidemiological studies.
Women with at least seven full-term pregnancies have a
three- to five-fold increased risk for development of CC
compared with nulliparous women. Number of pregnancies
is an important factor associated with CC lesions in the
female Mexican population.13
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